ZhiMin Shao, MD, PhD
Fudan University · Breast cancer institute of Fudan University Cancer Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name ZhiMin Shao, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:26 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06996093 · Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 InhibitorFudan University · not yet recruiting · Breast Cancer · principal investigator
- Ph2NCT06404463 · QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast CancerFudan University · not yet recruiting · Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer · principal investigator
- Ph3NCT06341621 · Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant AbemaciclibFudan University · recruiting · Breast Cancer · principal investigator
- Ph3NCT05954442 · Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypeFudan University · unknown · Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation · principal investigator
- Ph2NCT05949541 · Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerFudan University · recruiting · Breast Cancer, Advanced Breast Cancer · principal investigator
- Ph2NCT04734262 · A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Fudan University · active not recruiting · Metastatic Breast Cancer · principal investigator
- Ph3NCT04403529 · Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast CancerFudan University · unknown · Triple Negative Breast Cancer · principal investigator
- Ph3NCT04193059 · Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerFudan University · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT04129996 · A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)Fudan University · unknown · Triple-Negative Breast Cancer · principal investigator
- Ph3NCT03926091 · Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast CancerFudan University · unknown · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.